Beta-glucocerebrosidase (GCase)

Beta-glucocerebrosidase Overview

Beta-glucocerebrosidase (GCase) is a lysosomal glycoside hydrolase enzyme encoded by the GBA gene[2][1]. It catalyzes the critical step in glycolipid metabolism by hydrolyzing glucocerebroside into glucose and ceramide. GCase consists of 495–497 amino acids and has ~59 kDa molecular mass, featuring a TIM barrel catalytic domain and an immunoglobulin-like fold[1][6]. The enzyme is active at acidic pH, typical for lysosomal compartments. Mutations in the GBA gene prevent normal enzyme function, resulting in glucocerebroside accumulation, which leads to Gaucher disease—a condition with visceral and sometimes neuronal symptoms. GCase deficiency is also a major genetic risk factor for Parkinson’s disease, likely due to impaired lysosomal lipid turnover contributing to synuclein aggregation. Multiple drugs target this enzyme by supplementing its activity (enzyme replacement), stabilizing misfolded forms (pharmacological chaperones), or reducing substrate synthesis (substrate reduction therapy). The molecule is structurally and mechanistically well characterized, with a clear role in disease pathogenesis and therapeutic intervention[1][2][5][6][7].

Mechanism of Action

Enzyme replacement (supplementation of functional enzyme: imiglucerase, velaglucerase alfa, taliglucerase alfa); Pharmacological chaperone (binds and stabilizes mutant GCase in ER, improving folding and trafficking: ambroxol, arimoclomol); Substrate reduction (reducing glycosphingolipid synthesis: eliglustat)

Biological Functions

Safety Considerations

Interacting Drugs

Associated Biomarkers